Table 2.
Multivariable cause-specific hazards ratio of cancer-specific variables modelling for new-onset atrial fibrillation in breast cancer patients
| Variable | HR 0–90 days after cancer diagnosis (95% CI) | HR 91–180 days after cancer diagnosis (95% CI) | HR >180 days after cancer diagnosis (95% CI) |
|---|---|---|---|
| SEER stage | |||
| I (localized) | Ref | Ref | Ref |
| II (regional direct extension) | 2.52 (1.98–3.21) | 1.55 (1.05–2.27) | 1.69 (1.24–2.30) |
| III (regional lymph node extension only) | 1.50 (1.29–1.75) | 1.55 (1.28–1.88) | 1.48 (1.26–1.73) |
| IV (regional direct and lymph node extension) | 2.91 (2.35–3.61) | 2.65 (1.98–3.53) | 1.93 (1.47–2.53) |
| VII (distant) | 4.70 (4.04–5.48) | 3.48 (2.75–4.40) | 2.20 (1.72–2.83) |
| Surgical therapy | |||
| No surgery | 4.39 (3.80–5.07) | 2.83 (2.31–3.48) | 1.70 (1.39–2.07) |
| Localized therapy such as lumpectomy | ref | ref | Ref |
| Total simple mastectomy | 1.55 (1.31–1.85) | 1.20 (0.95–1.51) | 1.16 (0.97–1.40) |
| Modified radical mastectomy | 2.07 (1.75–2.44) | 1.63 (1.32–2.01) | 1.35 (1.13–1.62) |
| Variable | HRa |
|---|---|
| Laterality—left vs. right | 0.95 (0.89–1.02) |
| Grade | |
| 1 | Ref |
| 2 | 1.31 (1.18–1.46) |
| 3 | 1.92 (1.72–2.15) |
| 4 | 1.64 (0.98–2.76) |
| AJCC stage | |
| I | Ref |
| II | 1.51 (1.37–1.65) |
| III | 2.63 (2.35–2.94) |
| IV | 4.21 (3.74–4.74) |
| Radiation therapy | |
| No radiotherapy | 1.46 (1.34–1.59) |
| Beam radiation | Ref |
| Implanted radiation | 0.51 (0.37–0.70) |
| Tumour oestrogen receptor status vs. not | 0.66 (0.60–0.73) |
| Tumour progesterone receptor status vs. not | 0.72 (0.66–0.78) |
| Tumour HER2 status vs. not | 1.37 (1.19–1.58) |
| Breast tumour subtype based on combination receptor status | |
| HER2+/hormone receptor (HR)+ | Ref |
| HER2+/HR− | 1.26 (0.95–1.66) |
| HER2−/HR+ | 0.75 (0.63–0.89) |
| HER2−/HR− | 1.10 (0.89–1.36) |
Univariable analysis =presented in Supplementary material online, Table S1 was utilized in model building. All variables are adjusted for age, race, ethnicity, marital status, poverty level, urban location status, geographic SEER location, NCI comorbidity index, obesity, smoking, history of hypertension, history of depression, history of anaemia, and history of stroke. Lymph node biopsy status had >10% missing data and hence not modelled for. HER2 status and type of breast cancer included breast cancer patients after 2010.
CI, confidence interval; HER, human epidermal growth factor receptor; HR, hazard ratio; NCI, National Cancer Institute; SEER, Surveillance, Epidemiology, and End Results.
Variables at the latter part of the table meet proportional hazards assumption and presented hazard ratios are for the entire year.